Research Article Details
| Article ID: | A11761 |
| PMID: | 30762938 |
| Source: | Mol Nutr Food Res |
| Title: | Jamun (Eugenia jambolana Lam.) Fruit Extract Prevents Obesity by Modulating the Gut Microbiome in High-Fat-Diet-Fed Mice. |
| Abstract: | SCOPE: Published data support that gut microbiota play an important role in the pathological process of obesity and related metabolic disorders. In the current study, it is investigated whether a standardized extract from Jamun (Eugenia jambolana), a widely consumed tropical fruit, could alleviate obesity and alter gut microbial community in high-fat diet (HFD)-fed mice. METHODS AND RESULTS: C57BL/6 mice are fed either a standard diet (SD) or HFD with or without Jamun fruit extract (JFE; 100 mg kg-1 day-1 ) by oral gavage for 8 weeks. JFE supplementation significantly alleviated diet-induced obesity, insulin resistance, and liver steatosis. JFE supplementation also improved HFD-induced gut dysbiosis by restoring the ratio of Firmicutes to Bacteroidetes as revealed by 16S rDNA analyses. The relative abundance of certain genera, as well as levels and proportion of intestinal-derived short-chain fatty acids are improved in JFE-treated mice in comparison to the HFD-fed control group. CONCLUSION: These promising data show the potential association between gut microbiota modulation and metabolism improvement of the JFE administration, and support the utilization and further investigation of Jamun fruit as a dietary intervention strategy for the prevention of obesity and related metabolic disorders. |
| DOI: | 10.1002/mnfr.201801307 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S06 | Regulating intestinal flora | intestine gut microbiota; gut microbiota | farnesoid X receptor (FXR); fibroblast growth factor-19 (FGF19) | Probiotics; Prebiotics; Rifaximin; Yaq-001; Cilofexor; EDP-305; EYP001a; INT-767 | Details |
| S07 | Anti-lipogenesis | de novo lipogenesis; de novo lipogenesis; DNL; anti-lipogenic mechanisms; adipogenesis; anti-obesity | stearoyl-CoA desaturase 1 (SCD-1); Acetyl-coenzyme carboxylase; acyl-CoA carboxylase inhibitor (ACC inhibitor); stearoyl Coenzyme A desaturase inhibitor (SCD inhibitor); THR-beta selective agonist; DGAT2 inhibitor; FASN inhibitor | Aramchol; Firsocostat (GS-0976); VK-2809; ION 224 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |